Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Stevens Negus

Showing results (181-190 of 200) with videos related to

Pageof 20
Sort By:
Neuropharmacology|January 21, 2019
Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female ratsKathryn L Schwienteck, Kaycee E Faunce, Kenner C Rice, et al.
ACS Chemical Neuroscience|April 27, 2018
Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related BehaviorUmberto M Battisti, Ramsey Sitta, Alan Harris, et al.
Neuropharmacology|January 10, 2020
Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathyDana E Selley, Matthew F Lazenka, Laura J Sim-Selley, et al.
Pharmacological Reviews|February 4, 2026
Preclinical abuse potential testing using behavioral economics and drug self-administration demand-curve analysis: A strategy to improve resolution of drug stratification for regulatory controlMatthew L Banks, S Stevens Negus, Neil B Varshneya, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 29, 2018
Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142Megan J Moerke, Subramaniam Ananthan, Matthew L Banks, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 23, 2017
N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse LiabilityErnesto Solis, John S Partilla, Farhana Sakloth, et al.
Pharmacology, Biochemistry, and Behavior|May 13, 2008
Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeysHeather L Kimmel, S Stevens Negus, Kristin M Wilcox, et al.
Biological Psychiatry|April 20, 2020
In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain HypoxiaJennifer M Bossert, Eugene A Kiyatkin, Hannah Korah, et al.
ACS Chemical Neuroscience|November 30, 2022
Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine AnaloguesMengchu Li, David L Stevens, Michelle Arriaga, et al.
Experimental and Clinical Psychopharmacology|June 19, 2013
A method for conducting functional MRI studies in alert nonhuman primates: initial results with opioid agonists in male cynomolgus monkeysMarc J Kaufman, Amy C Janes, Blaise deB Frederick, et al.
Pageof 20

Showing results (181-190 of 200) with videos related to

Sort By:
Pageof 20
Neuropharmacology|January 21, 2019
Effectiveness comparisons of G-protein biased and unbiased mu opioid receptor ligands in warm water tail-withdrawal and drug discrimination in male and female ratsKathryn L Schwienteck, Kaycee E Faunce, Kenner C Rice, et al.
ACS Chemical Neuroscience|April 27, 2018
Effects of N-Alkyl-4-Methylamphetamine Optical Isomers on Plasma Membrane Monoamine Transporters and Abuse-Related BehaviorUmberto M Battisti, Ramsey Sitta, Alan Harris, et al.
Neuropharmacology|January 10, 2020
Attenuated dopamine receptor signaling in nucleus accumbens core in a rat model of chemically-induced neuropathyDana E Selley, Matthew F Lazenka, Laura J Sim-Selley, et al.
Pharmacological Reviews|February 4, 2026
Preclinical abuse potential testing using behavioral economics and drug self-administration demand-curve analysis: A strategy to improve resolution of drug stratification for regulatory controlMatthew L Banks, S Stevens Negus, Neil B Varshneya, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 29, 2018
Interactions between Cocaine and the Putative Allosteric Dopamine Transporter Ligand SRI-31142Megan J Moerke, Subramaniam Ananthan, Matthew L Banks, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|May 23, 2017
N-Alkylated Analogs of 4-Methylamphetamine (4-MA) Differentially Affect Monoamine Transporters and Abuse LiabilityErnesto Solis, John S Partilla, Farhana Sakloth, et al.
Pharmacology, Biochemistry, and Behavior|May 13, 2008
Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeysHeather L Kimmel, S Stevens Negus, Kristin M Wilcox, et al.
Biological Psychiatry|April 20, 2020
In a Rat Model of Opioid Maintenance, the G Protein-Biased Mu Opioid Receptor Agonist TRV130 Decreases Relapse to Oxycodone Seeking and Taking and Prevents Oxycodone-Induced Brain HypoxiaJennifer M Bossert, Eugene A Kiyatkin, Hannah Korah, et al.
ACS Chemical Neuroscience|November 30, 2022
Characterization of a Potential KOR/DOR Dual Agonist with No Apparent Abuse Liability via a Complementary Structure-Activity Relationship Study on Nalfurafine AnaloguesMengchu Li, David L Stevens, Michelle Arriaga, et al.
Experimental and Clinical Psychopharmacology|June 19, 2013
A method for conducting functional MRI studies in alert nonhuman primates: initial results with opioid agonists in male cynomolgus monkeysMarc J Kaufman, Amy C Janes, Blaise deB Frederick, et al.
Pageof 20